Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens

被引：37

作者：

Center, Rob J. ^{[1
]}

Wheatley, Adam K. ^{[1
]}

Campbell, Shahan M. ^{[1
]}

Gaeguta, Adriana J. ^{[1
]}

Peut, Viv ^{[1
]}

Alcantara, Sheilajen ^{[1
]}

Siebentritt, Carly ^{[1
]}

Kent, Stephen J. ^{[1
]}

Purcell, Damian F. J. ^{[1
]}

机构：

[1] Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3010, Australia

来源：

VACCINE | 2009年 / 27卷 / 47期

基金：

澳大利亚国家健康与医学研究理事会;

关键词：

HIV-1; Vaccine; Envelope protein; HUMAN-IMMUNODEFICIENCY-VIRUS; SIMIAN-HUMAN; ENVELOPE PROTEIN; VACCINE ELICITS; RHESUS-MONKEYS; EFFICACY; IMMUNIZATION; IMMUNITY; CLADE; PANEL;

D O I：

10.1016/j.vaccine.2009.08.016

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We developed highly expressing clade B and AE DNA and envelope protein (Env) vaccines for evaluation in mice and macaques as DNA prime/protein boost regimens. High levels of Env-specific antibodies were induced in mice, albeit with limited neutralizing activity in vitro. A combined clade B and AE regimen induced high titer Env-specific antibody in two pigtail macaques that neutralized several strains of HIV-1. However, upon mucosal challenge with SHIVSF162P3 no protection from infection was observed. Although the vaccines tested provide a platform for inducing robust humoral immunity, further refinements to broaden coverage against divergent strains and induce mucosal immunity are needed. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：6605 / 6612

页数：8

共 39 条

[1] DNA vaccination of macaques by a full-genome simian/human immunodeficiency virus type 1 plasmid chimera that produces non-infectious virus particles [J].

Akahata, W ;

Ido, E ;

Akiyama, H ;

Uesaka, H ;

Enose, Y ;

Horiuchi, R ;

Kuwata, T ;

Goto, T ;

Takahashi, H ;

Hayami, M .

JOURNAL OF GENERAL VIROLOGY, 2003, 84 :2237-2244

[2] Both linear and discontinuous ribosome scanning are used for translation initiation from bicistronic human immunodeficiency virus type 1 env mRNAs [J].

Anderson, Jenny L. ;

Johnson, Adam T. ;

Howard, Jane L. ;

Purcell, Damian F. J. .

JOURNAL OF VIROLOGY, 2007, 81 (09) :4664-4676

[3] Comparative evaluation of simian, simian-human, and human immunodeficiency virus infections in the pigtail macaque (Macaca nemestrina) model [J].

Batten, CJ ;

De Rose, R ;

Wilson, KM ;

Agy, MB ;

Chea, S ;

Stratov, I ;

Montefiori, DC ;

Kent, SJ .

AIDS RESEARCH AND HUMAN RETROVIRUSES, 2006, 22 (06) :580-588

[4] Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies [J].

Binley, JA ;

Wrin, T ;

Korber, B ;

Zwick, MB ;

Wang, M ;

Chappey, C ;

Stiegler, G ;

Kunert, R ;

Zolla-Pazner, S ;

Katinger, H ;

Petropoulos, CJ ;

Burton, DR .

JOURNAL OF VIROLOGY, 2004, 78 (23) :13232-13252

[5] Profiling the Specificity of Neutralizing Antibodies in a Large Panel of Plasmas from Patients Chronically Infected with Human Immunodeficiency Virus Type 1 Subtypes B and C [J].

Binley, James M. ;

Lybarger, Elizabeth A. ;

Crooks, Emma T. ;

Seaman, Michael S. ;

Gray, Elin ;

Davis, Katie L. ;

Decker, Julie M. ;

Wycuff, Diane ;

Harris, Linda ;

Hawkins, Natalie ;

Wood, Blake ;

Nathe, Cory ;

Richman, Douglas ;

Tomaras, Georgia D. ;

Bibollet-Ruche, Frederic ;

Robinson, James E. ;

Morris, Lynn ;

Shaw, George M. ;

Montefiori, David C. ;

Mascola, John R. .

JOURNAL OF VIROLOGY, 2008, 82 (23) :11651-11668

[6] Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines [J].

Brown, BK ;

Darden, JM ;

Tovanabutra, S ;

Oblander, T ;

Frost, J ;

Sanders-Buell, E ;

de Souza, MS ;

Birx, DL ;

McCutchan, FE ;

Polonis, VR .

JOURNAL OF VIROLOGY, 2005, 79 (10) :6089-6101

[7] GENERATION OF HUMAN MONOCLONAL-ANTIBODIES AGAINST HIV-1 PROTEINS - ELECTROFUSION AND EPSTEIN-BARR-VIRUS TRANSFORMATION FOR PERIPHERAL-BLOOD LYMPHOCYTE IMMORTALIZATION [J].

BUCHACHER, A ;

PREDL, R ;

STRUTZENBERGER, K ;

STEINFELLNER, W ;

TRKOLA, A ;

PURTSCHER, M ;

GRUBER, G ;

TAUER, C ;

STEINDL, F ;

JUNGBAUER, A ;

KATINGER, H .

AIDS RESEARCH AND HUMAN RETROVIRUSES, 1994, 10 (04) :359-369

[8] Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial [J].

Buchbinder, Susan P. ;

Mehrotra, Devon V. ;

Duerr, Ann ;

Fitzgerald, Daniel W. ;

Mogg, Robin ;

Li, David ;

Gilbert, Peter B. ;

Lama, Javier R. ;

Marmor, Michael ;

del Rio, Carlos ;

McElrath, M. Juliana ;

Casimiro, Danilo R. ;

Gottesdiener, Keith M. ;

Chodakewitz, Jeffrey A. ;

Corey, Lawrence ;

Robertson, Michael N. .

LANCET, 2008, 372 (9653) :1881-1893

[9] Oligomeric structure of the human immunodeficiency virus type I envelope protein on the virion surface [J].

Center, RJ ;

Leapman, RD ;

Lebowitz, J ;

Arthur, LO ;

Earl, PL ;

Moss, B .

JOURNAL OF VIROLOGY, 2002, 76 (15) :7863-7867

[10] Promoting trimerization of soluble human immunodeficiency virus type 1 (HIV-1) Env through the use of HIV-1/simian immunodeficiency virus chimeras [J].

Center, RJ ;

Lebowitz, J ;

Leapman, RD ;

Moss, B .

JOURNAL OF VIROLOGY, 2004, 78 (05) :2265-2276

← 1 2 3 4 →